SBFM - Sunshine Biopharma, Inc. Stock Analysis

Stock Taper

SCREENER COMPARE ANY 2 STOCKS

SBFM

SUNSHINE BIOPHARMA, INC.

NASDAQ

$1.13

▲ UP 1.82% (0.02)

KEY STATISTICS

Market Cap$2.69 M

52w High$24.30

52w Low$1.01

Dividend Yield—

Frequency—

P/E-0.19

Volume70.44K

Shares Out.2.38M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Steve N. Slilaty

COMPENSATION 2026

Salary$378,000

Stock Awards$0

Incentive Plan Pay$0

All Other Comp.$0

Total$560,000

ABOUT

SECTOR

Healthcare

WENT PUBLIC

February 15, 2022

METHOD OF GOING PUBLIC

IPO

FULL TIME EMPLOYEES

UPCOMING EARNINGS

DateNov 12, 2026

DayThursday

Rev. Est.$9.60M

NOV

THU

SPLIT RECORD

DATE	TYPE	RATIO
2026-06-01	Reverse	1:10
2024-08-08	Reverse	1:20
2024-04-17	Reverse	1:100
2022-02-09	Reverse	1:200
2020-04-06	Reverse	1:20
2019-02-01	Reverse	1:20

PRICE

$1.13 ▲ UP 1.82% (+$0.02)

OVERLAYS

About Sunshine Biopharma, Inc.

https://www.sunshinebiopharma.com ↗

Sunshine Biopharma, Inc. develops anticancer drugs like Adva-27a and antiviral compounds such as SBFM-PL4, alongside nutritional supplements, focusing on innovative treatments for various cancers and coronavirus, based in Pointe-Claire, Canada.

INDUSTRY

Drug Manufacturers - Specialty & Generic

A PRODUCT SUNSHINE BIOPHARMA, INC. IS KNOWN FOR

Niopeg

Sunshine Biopharma's subsidiary Nora Pharma launched its first biosimilar to Neulasta, aimed at reducing infections in chemotherapy patients and marking the company's entry into the high-value biologics market.